middle.news
CSL to Begin Clinical Trials for Yield-Boosting Horizon 2 Plasma Process in 2027
9:21am on Wednesday 29th of July, 2026 AEST
•
Healthcare
Read Story
CSL to Begin Clinical Trials for Yield-Boosting Horizon 2 Plasma Process in 2027
9:21am on Wednesday 29th of July, 2026 AEST
Key Points
Horizon 2 aims to increase immunoglobulin yield from plasma
Clinical trials to start mid-2027 at Broadmeadows facility
Trials support FDA and EMA regulatory approval processes
Manufacturing expansion underway at Kankakee, Illinois
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CSL (ASX:CSL)
OPEN ARTICLE